Meningococcal Vaccines Market Overview and Introduction

Meningococcal disease is caused by a Gram-negative bacterium referred to as Neisseria meningitidis. The bacterium has at least 13 different subtypes (serogroups) out of which five of the serogroups A, B, C, Y, and W causes invasive diseases in humans. Meningococcal vaccine is administered to defend individuals from bacterial infection which causes meningitis. The vaccine contains a small amount of killed bacteria which assists the body to produce antibodies in case of encounter with a bacteria during future exposures. Meningococcal vaccines are broadly classified into polysaccharide vaccines and conjugate meningococcal vaccines. Polysaccharide vaccines are composed of purified, heat-stable, lyophilized capsular polysaccharides from respective serogroups of meningococci. Whereas, conjugate meningococcal vaccines provides prolonged duration of protection as they are composed of bacterial polysaccharide conjugated with a protein carrier which induces a T-cell-dependent immune response, providing increased immunogenicity among infants.

Rising incidences of meningitis worldwide is likely to propel the growth of the global meningococcal vaccines market. Moreover, supportive government initiatives and growing efforts of healthcare organizations to curb meningococcal disease have been pivotal in contributing to the extensive growth of the global meningococcal vaccines market. However, the additional cost of cold storage required for vaccine maintenance is likely to hamper the growth of the global meningococcal market.

The global meningococcal vaccines market is segmented by vaccine type, patient type and region.

Meningococcal Vaccines Market by Vaccine Type

On the basis of vaccine type, the meningococcal vaccines market is segmented into polysaccharide-based vaccines, quadrivalent conjugate vaccines, serogroup B vaccines and others. Quadrivalent conjugate vaccines is estimated to account for the largest share in global meningococcal vaccines market in 2018. The immunogenicity of polysaccharide is enhanced by coupling to protein carriers in quadrivalent conjugate vaccines which ultimately provides enhanced immune response, thereby, ensuring greater administration of quadrivalent conjugate type of vaccine among the population.

Meningococcal Vaccines Market by Patient Type

Similarly, in terms of patient type the meningococcal vaccines market can be segmented into pediatric patients and adult patients. Pediatric patients segment account for the largest share in 2019, owing to rising number of immunization & vaccination programs worldwide, for a wide range of diseases including meningitis, polio, chicken pox, and measles among others.

Meningococcal Vaccines Market by Region

The global meningococcal vaccines market can be segmented into North America, Europe, Asia Pacific, and Rest of World (ROW). North America dominated the meningococcal vaccines market, followed by Europe and Asia Pacific. The large share of this region can be attributed to extensive research & development studies on diseases & ailments and supportive government initiatives to promote & encourage immunization programs for a broad range of diseases.

Meningococcal Vaccines Market Prominent Players

The prominent players in the meningococcal vaccines market are GlaxoSmithKline plc., Sanofi, Pfizer Inc., Serum Institute of India Pvt. Ltd, Nuron Biotech Inc., BIO-MED, Hualan Biological Engineering Inc, Walvax Biotechnology Co., Ltd. and other key players (if any) among others.